Tolebrutinib’s potential approval as the first brain-penetrant BTK inhibitor for non-relapsing secondary progressive MS could represent a paradigm shift in treating disability driven by smoldering neuroinflammation.:
Source: Neurology Read More
FDA Accepts Regulatory Submission for BTK Inhibitor Tolebrutinib for Non-Relapsing Secondary Progressive MS
Related Posts
<![CDATA[FDA AdComm Votes Against Recommending
Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in
AD, Salanersen’s FDA Breakthrough Designation
Meaning]]>
<![CDATA[FDA AdComm Votes Against Recommending Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in AD, Salanersen’s FDA Breakthrough Designation Meaning]]>
